Lexaria Bioscience (LEXX) Research & Development (2017 - 2026)
Lexaria Bioscience's (LEXX) quarterly Research & Development came in at $475388.0 in Q1 2026, down 71.8% year-on-year from $1.7 million in Q1 2025, and down 29.19% quarter-over-quarter from $671340.0 in Q4 2025.
Lexaria Bioscience (LEXX) Research & Development (2017 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Research & Development across 10 years of filings, most recently posting $475388.0 for Q1 2026.
- Research & Development for Q1 2026 came in at $475388.0, down 71.8% year-over-year; the trailing twelve-month figure through Feb 2026 was $5.7 million (up 10.95% YoY), and the FY2025 annual result was $8.2 million, up 249.02% from the prior year.
- Research & Development came in at $475388.0 for Q1 2026 at Lexaria Bioscience, down from $671340.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.7 million in Q2 2025 to a low of $245779.0 in Q1 2024.
- The 5-year median for Research & Development is $696178.0 (2023), against an average of $988043.5.
- Across the five-year window, Research & Development soared 585.95% in 2025 and tumbled 71.8% in 2026, its largest moves.
- Lexaria Bioscience's Research & Development stood at $829489.0 in 2022, then sank by 30.74% to $574491.0 in 2023, then soared by 239.99% to $2.0 million in 2024, then tumbled by 65.63% to $671340.0 in 2025, then slipped by 29.19% to $475388.0 in 2026.
- The last three Research & Development figures came in at $475388.0 (Q1 2026), $671340.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | 475,388.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 475,388.00 |
| Nov 30, 2025 | 671,340.00 |
| Aug 31, 2025 | 1.88 Mn |
| May 31, 2025 | 2.72 Mn |
| Feb 28, 2025 | 1.69 Mn |
| Nov 30, 2024 | 1.95 Mn |
| Aug 31, 2024 | 967,206.00 |
| May 31, 2024 | 573,089.00 |
| Feb 29, 2024 | 245,779.00 |
| Nov 30, 2023 | 574,491.00 |
| Aug 31, 2023 | 500,406.00 |
| May 31, 2023 | 1.64 Mn |
| Feb 28, 2023 | 696,178.00 |
| Nov 30, 2022 | 829,489.00 |
| Aug 31, 2022 | 356,188.00 |
| May 31, 2022 | 752,095.00 |
| Feb 28, 2022 | 275,686.00 |
| Nov 30, 2021 | 458,709.00 |
| Aug 31, 2021 | 439,793.00 |
| May 31, 2021 | 454,443.00 |